FDA Grants Priority Review for Frontline Pembrolizumab Combo in NSCLCApril 30th 2018
The FDA has granted a priority review for frontline use of the PD-1 inhibitor pembrolizumab (Keytruda) in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.
FDA Grants Nivolumab Priority Review for SCLC TreatmentApril 19th 2018
The FDA has granted priority review to a supplemental biologics license application for nivolumab (Opdivo) to be used to treat patients with small cell lung cancer who have already had two or more lines of therapy, and whose disease has continued to progress.
Nurses Play Critical Role in New Dosing Regimen for NivolumabMarch 20th 2018
While the new FDA approval of 4-week dosing adds more flexibility in scheduling, it reduces the number of times patients would be monitored in person for adverse effects (AEs), so nurses need to be alert to and educated about potential AEs.
NCCN, ASCO Guide Nurses in Managing Checkpoint Inhibitor Side EffectsFebruary 20th 2018
Recognizing and understanding how to manage side effects related to immunotherapy treatements is key for nurses. To educate healthcare teams on immunotherapy-related toxicities, The National Comprehensive Cancer Network and the American Society of Clinical Oncology issued new guidelines.
Dense Tissue Is Not an Obstacle to Immunotherapy in Desmoplastic MelanomaJanuary 31st 2018
Researchers have recently discovered that immunotherapy agents have potential to effectively treat desmoplastic melanoma, even though the dense tissue associated with this rare cancer would seem to preclude it.
Ovarian Cancer Research Pivots Toward Combination TherapiesJanuary 31st 2018
Immunotherapy alone has not shown much success in treating ovarian cancer, despite success with other cancers, so researchers are now testing combinations of immunotherapy drugs with other agents to see if it enhances effectiveness.
Emerging Treatments in Bladder CancerJanuary 25th 2018
The year 2017 saw significant advancements in the field of bladder cancer treatment. Five Food and Drug Administration (FDA) approvals for checkpoint inhibitors in both the first and second line setting opened up the immunotherapy landscape, and more develoments are on the way.
Expert Examines Immunotherapy's Role in Squamous Cell Lung CancerNovember 29th 2017
“Immunotherapy is a new option for patients and is well established,” said George R. Blumenschein, MD. “We are refining how we use it. There will be a number of additional refinements as we have the new data that will be coming forward in the next few months.”
Advice to Nurses on Handling Immunotherapy's Side EffectsNovember 27th 2017
In an interview with Oncology Nursing News, the assistant professor at the Yale School of Nursing discussed a new standard of care with immunotherapy, common side effects, and why patients sometimes withhold information from their healthcare team.
Nivolumab Gains Approval for MSI-H or dMMR Colorectal CancerAugust 1st 2017
The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
Immunotherapy A First in Treating Merkel Cell CarcinomaJuly 19th 2017
The immunotherapy agent, avelumab (Bavencio) is the first drug to receive approval to treat Merkel cell carcinoma (MCC), a rare form of skin cancer. Carrie Best was the first patient to enroll in a clinical trial of avelumab, the first to receive the drug for Merkel cell carcinoma, and the first to become cancer-free.